الرئيسية › الورم النقوي المتعدد › تينيسي › Nashville
التجارب السريرية لـ الورم النقوي المتعدد في Nashville، TN
32 دراسات لـ الورم النقوي المتعدد تبحث عن مشاركين في مواقع داخل وحول Nashville (ضمن نطاق 30 ميلًا تقريبًا). افتح الدراسة لمعرفة من يمكنه المشاركة وكيفية التواصل مع فريق الدراسة.
النص الرسمي للدراسة (بالإنجليزية)
تبحث عن مشاركين لدراسة؟ أبرزها في أعلى الصفحة — $99 لمدة 30 يومًا →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
جارٍ التسجيلالمرحلة 3
- Research Site, Nashville
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
جارٍ التسجيلالمرحلة 4
- Sarah Cannon Research Institute, Nashville
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
جارٍ التسجيلالمرحلة 3
- SCRI Oncology Partners, Nashville
- Vanderbilt University Medical Center, Nashville
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
جارٍ التسجيلالمرحلة 3
- Tennessee Oncology, PLLC, Nashville
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
جارٍ التسجيلالمرحلة 1
- Research Site, Nashville
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
جارٍ التسجيلالمرحلة 3
- Henry-Joyce Cancer Clinic, Nashville
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
جارٍ التسجيلالمرحلة 1/2
- Sarah Cannon Research Institute, Nashville
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
جارٍ التسجيلالمرحلة 2
- Tennessee Oncology - Nashville / Sarah Cannon Research Institute, Nashville
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
جارٍ التسجيلالمرحلة 2/3
- SCRI Oncology Partners /ID# 278353, Nashville
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
جارٍ التسجيلالمرحلة 2
- Tennessee Oncology, Nashville
- Vanderbilt University Medical Center, Nashville
A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
جارٍ التسجيلالمرحلة 2
- SCRI Oncology Partners, Nashville
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
جارٍ التسجيلالمرحلة 1
- Tennessee Oncology, Nashville
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
جارٍ التسجيلالمرحلة 1/2
- Research Site, Nashville
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
جارٍ التسجيلالمرحلة 2
- GSK Investigational Site, Nashville
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
جارٍ التسجيلالمرحلة 3
- Ascension St. Thomas Hospital, Nashville
- Tennessee Oncology, PLLC - Investigational Drug Services, Nashville
- Tennessee Oncology, PLLC - Nashville Elliston Place Plaza Center for Blood Cancers, Nashville
- و 2 أخرى
Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing
جارٍ التسجيلالمرحلة 2
- Vanderbilt University Medical Center, Nashville
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
جارٍ التسجيلالمرحلة 1/2
- GSK Investigational Site, Nashville
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
جارٍ التسجيلالمرحلة 1
- Tennessee Oncology, Nashville
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
جارٍ التسجيلالمرحلة 1/2
- SCRI Oncology Partners, Nashville
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
جارٍ التسجيلالمرحلة 1/2
- Research Site, Nashville
- Research Site, Nashville
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
جارٍ التسجيلالمرحلة 3
- Research Site, Nashville
- Research Site, Nashville
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
جارٍ التسجيلالمرحلة 2
- Tennessee Oncology, Nashville
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
جارٍ التسجيلالمرحلة 1
- Tennessee Oncology, Nashville
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
جارٍ التسجيلالمرحلة 1
- Vanderbilt Ingram Cancer Center /ID# 252470, Nashville
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
جارٍ التسجيلالمرحلة 3
- Vanderbilt-Ingram Cancer Center (VICC), Nashville
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
جارٍ التسجيلالمرحلة 2
- SCRI Oncology Partners, Nashville
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
جارٍ التسجيلالمرحلة 2
- TriStar Bone Marrow Transplant, Nashville
- Vanderbilt- Ingram Cancer Center, Nashville
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
جارٍ التسجيلالمرحلة 1/2
- TriStar Centennial Medical Center, Nashville
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
جارٍ التسجيلالمرحلة 1
- Local Institution - 0008, Nashville
- Tennessee Oncology, Nashville
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
جارٍ التسجيلدراسة رصديةمرحباً بالمتطوعين الأصحاء
- Vanderbilt-Ingram Cancer Center, Nashville
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
جارٍ التسجيلالمرحلة 1
- Tennessee Oncology, Nashville
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
جارٍ التسجيلالمرحلة 1/2
- SCRI Oncology Partners, Nashville
تجارب الورم النقوي المتعدد في مدن أخرى
- New York City, NY60 دراسات
- Boston, MA42 دراسات
- Atlanta, GA42 دراسات
- Houston, TX38 دراسات
- Durham, NC37 دراسات
- Denver, CO27 دراسات
- Rochester, MN24 دراسات
- St. Louis, MO24 دراسات
- Columbus, OH24 دراسات
- Baldwin Park, CA23 دراسات
- Edison, NJ22 دراسات
- Chicago, IL22 دراسات
دراسات أخرى في Nashville
- سرطان الرئة غير صغير الخلايا97 دراسات
- سرطان الثدي81 دراسات
- السرطان النقيلي70 دراسات
- سرطان القولون والمستقيم69 دراسات
- السرطان (جميع الأنواع)65 دراسات
- سرطان المبيض49 دراسات
- سرطان البروستاتا43 دراسات
- سرطان الرئة40 دراسات
- سرطان الخلايا الحرشفية في الرأس والرقبة39 دراسات
- سرطان البنكرياس39 دراسات
- سرطان بطانة الرحم38 دراسات
- ميلانوما33 دراسات
من ClinicalTrials.gov، البيانات مستخرجة في 06/10/2026. كل دراسة تحدد معايير أهليتها الخاصة؛ فريق الدراسة هو من يحدد من يمكنه المشاركة.